Literature DB >> 1233230

Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men.

J H Atterhög, L G Ekelund.   

Abstract

Verapamil, 0.1 mg/kg body wt, was injected i.v. over 2 minutes in 8 subjectively healthy middle-aged men, followed by a continuous infusion of 0.007 mg/kg body wt per minute. Prior to the injection several of the subjects had raised pulmonary or systemic arterial pressures. At rest, the central pressures increased slightly, which was taken as a sign of a moderate negative inotropic effect, but there was no change in pre-ejection period or maximal dp/dt of the aortic pressure. The heart rate increased and there was a small decrease in systemic arterial pressure, probably due to a fall of systemic vascular resistance. The PQ time was prolonged. During exercise, with its positive inotropic stimulation, the moderate negative inotropic effect of verapamil disappeared, whereas the increase in heart rate and decrease in aortic pressures persisted. Some variables that reflected the oxygen demand of the heart decreased. The slight negative inotropic effect does not appear to be a particular contraindication to the use of verapamil, but it should be employed cautiously in conditions with a compensatory rise in systemic vascular resistance, or if atrioventricular conduction is impaired.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233230     DOI: 10.1007/bf00562656

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  HEART VOLUME AND ITS RELATION TO ANTHROPOMETRIC DATA IN OLD MEN COMPARED WITH YOUNG MEN.

Authors:  T STRANDELL
Journal:  Acta Med Scand       Date:  1964-08

2.  [(N-methyl-N-homoveratryl)-gamma-aminopropyl]-3,4-dimethoxyphenyl-acetonitrile, a substance with coronary vasodilating properties].

Authors:  H HAAS; G HAERTFELDER
Journal:  Arzneimittelforschung       Date:  1962-06

3.  Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle.

Authors:  W G Nayler; J Szeto
Journal:  Cardiovasc Res       Date:  1972-03       Impact factor: 10.787

4.  The use of indirect indices of myocardial oxygen consumption in evaluating angina pectoris.

Authors:  R E Goldstein; S E Epstein
Journal:  Chest       Date:  1973-03       Impact factor: 9.410

5.  A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function.

Authors:  B N Singh
Journal:  Cardiovasc Res       Date:  1972-03       Impact factor: 10.787

6.  Immediate effects of intravenous verapamil on atrial fibrillation.

Authors:  L Schamroth
Journal:  Cardiovasc Res       Date:  1971-10       Impact factor: 10.787

7.  On the cardiac adrenergic blocking action of iproveratril in normal and coronary-ligated dogs.

Authors:  K I Melville; H L Garvey; H E Shister
Journal:  Rev Can Biol       Date:  1968-09

8.  [Clinical experimental studies on the blood pressure reducing effect of verapamil].

Authors:  W D Brittinger; A Schwarzbeck; K W Wittenmeier; W D Twittenhoff; B Stegaru; W Huber; R W Ewald; G E von Henning; M Fabricius; M Strauch
Journal:  Dtsch Med Wochenschr       Date:  1970-09-11       Impact factor: 0.628

9.  Immediate effects of intravenous verapamil in cardiac arrhythmias.

Authors:  L Schamroth; D M Krikler; C Garrett
Journal:  Br Med J       Date:  1972-03-11

10.  [The antiarrhythmic action mechanism of verapamil (Isoptin)].

Authors:  O Bass; M Friedemann
Journal:  Schweiz Med Wochenschr       Date:  1971-05-29
View more
  10 in total

1.  Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.

Authors:  P Rocha; M Guerret; D David; X Marchand; J C Kahn
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 2.  Calcium antagonists. Clinical use in the treatment of systemic hypertension.

Authors:  C Spivack; S Ocken; W H Frishman
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

3.  Comparison of two calcium antagonists, verapamil and fendiline, in an experimental model of myocardial ischaemia mimicking classical angina on effort.

Authors:  V Csik; L Szekeres; E Udvary
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

Review 4.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

Review 5.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

6.  Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy.

Authors:  K Landmark; S Sire; E Thaulow; J P Amlie; S Nitter-Hauge
Journal:  Br Heart J       Date:  1982-07

Review 7.  Verapamil: a review of its pharmacological properties and therapeutic use.

Authors:  B N Singh; G Ellrodt; C T Peter
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

8.  Effects of verapamil on pulmonary haemodynamics during hypoxaemia, at rest, and during exercise in patients with chronic obstructive pulmonary disease.

Authors:  S E Brown; G S Linden; R R King; G P Blair; D W Stansbury; R W Light
Journal:  Thorax       Date:  1983-11       Impact factor: 9.139

9.  Calcium antagonist drugs in chronic stable angina. Comparison of verapamil and nifedipine.

Authors:  J R Dawson; N H Whitaker; G C Sutton
Journal:  Br Heart J       Date:  1981-11

Review 10.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.